Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Stella Pharma Corporation
4888Stella Pharma Corporation engages in the research, development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its product includes SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma and meningioma, and malignant melanoma and angiosarcoma. The company was incorporated in 2007 and is headquartered in Osaka, Japan. Address: ORIX Kouraibashi Building, Osaka, Japan, 541-0043
Analytics
Objectif de Cours de WallStreet
–Ratio C/B
–Rendement du dividende
–Chiffres clés 4888
- Marge Bénéficiaire
- Revenu Total
- Bénéfice Brut
- Revenu Net
Analyse des dividendes 4888
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y>5 - expected 5-9 dividend yield on cost over 10Y<5 - expected <5 dividend yield on cost over 10YMaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes 4888
- Ratio de Distribution
- Dividends
- Rendement du dividende
Valorisation des titres 4888
- Prix sur Revenu
- Ratio PE
- Prix sur Valeur Comptable
- Ratio de Liquidité Courante
- Ratio d'Endettement
financières 4888
Résultats | 2019 | Dynamique |